The challenge we all have is managing expectations
Post# of 30025
Posted On: 02/04/2015 11:53:28 AM
Re: biotechmania #16292
The challenge we all have is managing expectations. The stock price used to be more resilient. It really moved based on good news, or expectations of good news.
For example, I remember back in 2013 when it went from .03 cents to .09 cents based on Maart Sarma getting a grant to study MANF on diabetes. After everyone realized the study would take some time and nothing more was imminent, the pps went back down to .045 cents after a few weeks, but at least it showed movement based on news.
Then in January of 2014 it went from .06 cents to .137 cents based on hopes of a Lympro partner, but when that didn't happen it went back down to .07 cents.
Then again in June of 2014 the stock went from .07 cents all the way up to .193 cents based on hopes the Lympro data would be great and a partnership would follow....but when it didn't happen, we went down to .07 cents again, where we have more or less stayed for 6 months.
The stock no longer shows movement based on good news anymore, or even expectations of good news. (The Boy Who Cried Wolf Syndrome)
This isn't a bad thing. It means that both management and shareholders are becoming more realistic about the stock. In the end it is usually infusion of MONEY that gets a small Bio-tech penny stock moving: revenue, JV money, grants, etc. Once the movement upward is sustainable, they then up list and institutional investors help grow the company.
Hard to say when MONEY will transform us. MJFF could supply a nice grant for Eltoprazine and that might be nice. Some Partner could step in on the Diagnostic Company. The Congressmen Gerald spoke with about Lympro in that article yesterday could mean funding is coming. LymPro should start making some sales. The MS diagnostic is only 3 or 4 months away from actual revenue. Some combination of these things will happen in the coming weeks and months and we'll get out of this "The Boy That Cried Wolf Syndrome" and the pps will be more responsive to news again. We're going to soar, but MONEY must come in first to light the fuse!!
For example, I remember back in 2013 when it went from .03 cents to .09 cents based on Maart Sarma getting a grant to study MANF on diabetes. After everyone realized the study would take some time and nothing more was imminent, the pps went back down to .045 cents after a few weeks, but at least it showed movement based on news.
Then in January of 2014 it went from .06 cents to .137 cents based on hopes of a Lympro partner, but when that didn't happen it went back down to .07 cents.
Then again in June of 2014 the stock went from .07 cents all the way up to .193 cents based on hopes the Lympro data would be great and a partnership would follow....but when it didn't happen, we went down to .07 cents again, where we have more or less stayed for 6 months.
The stock no longer shows movement based on good news anymore, or even expectations of good news. (The Boy Who Cried Wolf Syndrome)
This isn't a bad thing. It means that both management and shareholders are becoming more realistic about the stock. In the end it is usually infusion of MONEY that gets a small Bio-tech penny stock moving: revenue, JV money, grants, etc. Once the movement upward is sustainable, they then up list and institutional investors help grow the company.
Hard to say when MONEY will transform us. MJFF could supply a nice grant for Eltoprazine and that might be nice. Some Partner could step in on the Diagnostic Company. The Congressmen Gerald spoke with about Lympro in that article yesterday could mean funding is coming. LymPro should start making some sales. The MS diagnostic is only 3 or 4 months away from actual revenue. Some combination of these things will happen in the coming weeks and months and we'll get out of this "The Boy That Cried Wolf Syndrome" and the pps will be more responsive to news again. We're going to soar, but MONEY must come in first to light the fuse!!
(0)
(0)